Michael R McDevitt

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Targeted alpha particle immunotherapy for myeloid leukemia
    Joseph G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Blood 100:1233-9. 2002
  2. ncbi request reprint Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates
    Matthias Miederer
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 45:129-37. 2004
  3. pmc Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes
    Alessandro Ruggiero
    Department of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Nanomedicine 5:783-802. 2010
  4. ncbi request reprint Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes
    Michael R McDevitt
    Molecular Pharmacology and Chemistry Department, Departments of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 48:1180-9. 2007
  5. pmc PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice
    Michael R McDevitt
    Molecular Pharmacology and Chemistry Department, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 2:e907. 2007
  6. ncbi request reprint Efforts to control the errant products of a targeted in vivo generator
    Jaspreet Singh Jaggi
    Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 65:4888-95. 2005
  7. pmc Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization
    Jaspreet Singh Jaggi
    Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 2:e267. 2007
  8. ncbi request reprint Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression
    Ase M Ballangrud
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:4489-97. 2004
  9. pmc Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators
    Christophe Antczak
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Bioconjug Chem 17:1551-60. 2006
  10. ncbi request reprint Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys
    Jaspreet Singh Jaggi
    Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 64:1503-12. 2006

Research Grants

Collaborators

Detail Information

Publications30

  1. ncbi request reprint Targeted alpha particle immunotherapy for myeloid leukemia
    Joseph G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Blood 100:1233-9. 2002
    ..This study demonstrates the safety, feasibility, and antileukemic effects of (213)Bi-HuM195, and it is the first proof-of-concept for systemic targeted alpha particle immunotherapy in humans...
  2. ncbi request reprint Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates
    Matthias Miederer
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 45:129-37. 2004
    ..However, the 3 alpha-emitting daughter elements generated have the potential for significant toxicity as these nuclides are no longer bound to the carrier IgG...
  3. pmc Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes
    Alessandro Ruggiero
    Department of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Nanomedicine 5:783-802. 2010
    ..These data have implications that support further imaging and radiotherapy studies using a SWCNT-based platform and focusing on the tumor vessels as the target...
  4. ncbi request reprint Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes
    Michael R McDevitt
    Molecular Pharmacology and Chemistry Department, Departments of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 48:1180-9. 2007
    ..We hypothesized that novel prototype nanostructures consisting of biologics, radionuclides, fluorochromes, and CNT could be synthesized and designed to target tumor cells...
  5. pmc PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice
    Michael R McDevitt
    Molecular Pharmacology and Chemistry Department, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 2:e907. 2007
    ....
  6. ncbi request reprint Efforts to control the errant products of a targeted in vivo generator
    Jaspreet Singh Jaggi
    Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 65:4888-95. 2005
    ..0001). Metal chelation, diuresis with furosemide or chlorothiazide, and competitive metal blockade may be used as adjuvant therapies to modify the renal accumulation of 225Ac daughters...
  7. pmc Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization
    Jaspreet Singh Jaggi
    Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 2:e267. 2007
    ..Alpha particles are extraordinarily potent, short-ranged radiations with geometry uniquely suitable for selectively killing neovasculature...
  8. ncbi request reprint Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression
    Ase M Ballangrud
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:4489-97. 2004
    ..225)Ac has a 10-day half-life and a decay scheme yielding four alpha-particles...
  9. pmc Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators
    Christophe Antczak
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Bioconjug Chem 17:1551-60. 2006
    ..The excretion mechanisms of radiolabeled fragments seem to constitute a major limiting step in the chain of events leading to their clearance...
  10. ncbi request reprint Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys
    Jaspreet Singh Jaggi
    Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 64:1503-12. 2006
    ..We attempted to modify pharmacologically, the functional and morphologic changes in mouse kidneys after injection with the actinium ((225)Ac) nanogenerator, an in vivo generator of alpha- and beta-particle emitting elements...
  11. ncbi request reprint Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters
    Jaspreet Singh Jaggi
    Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Soc Nephrol 16:2677-89. 2005
    ..These findings are dissimilar to those seen after gamma or beta irradiation of kidneys...
  12. pmc Paradoxical glomerular filtration of carbon nanotubes
    Alessandro Ruggiero
    Departments of Medicine, Radiology, Molecular Pharmacology and Chemistry or the Molecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 107:12369-74. 2010
    ....
  13. pmc Synthesis and biodistribution of oligonucleotide-functionalized, tumor-targetable carbon nanotubes
    Carlos H Villa
    Molecular Pharmacology and Chemistry Program and Departments of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nano Lett 8:4221-8. 2008
    ..Appended RGD ligands allowed for specific binding to tumor cells in a flow cytometric assay. The techniques employed should enable the synthesis of multifunctional SWNT capable of self-assembly in biological settings...
  14. pmc Enhanced retention of the alpha-particle-emitting daughters of Actinium-225 by liposome carriers
    Stavroula Sofou
    Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Bioconjug Chem 18:2061-7. 2007
    ....
  15. ncbi request reprint Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2
    Matthias Miederer
    Departments of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:6985-92. 2004
    ..The (225)Ac-3F8 treatment improved survival 2-fold from 16 to 34 days (P = 0.01). In conclusion, in vivo alpha generators targeted by 3F8 warrant additional study as a possible new approach to the treatment of carcinomatous meningitis...
  16. ncbi request reprint Targeted actinium-225 in vivo generators for therapy of ovarian cancer
    Paul E Borchardt
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 63:5084-90. 2003
    ..In conclusion, i.p. administration with a (225)Ac-labeled internalizing anti-HER-2/neu antibody can extend survival significantly in a nude mouse model of human ovarian cancer at levels that produce no apparent gross toxicity...
  17. pmc Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors
    Freddy E Escorcia
    Molecular Pharmacology and Chemistry Program, Cancer Biology and Genetics Program, and Departments of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer Res 70:9277-86. 2010
    ..Moreover, targeting the vessel for killing provides an alternative mode of improving chemotherapy delivery and efficacy, potentially avoiding some of the drawbacks of targeting a highly redundant angiogenic pathway...
  18. ncbi request reprint Actinium-225 in targeted alpha-particle therapeutic applications
    David A Scheinberg
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Curr Radiopharm 4:306-20. 2011
    ..Targeting 225Ac-drug constructs have potential in the treatment of cancer...
  19. doi request reprint Conscripts of the infinite armada: systemic cancer therapy using nanomaterials
    David A Scheinberg
    Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Rev Clin Oncol 7:266-76. 2010
    ....
  20. pmc Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia
    Todd L Rosenblat
    Department of Medicine and the Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:5303-11. 2010
    ..This phase I/II trial was conducted to determine the maximum tolerated dose (MTD) and antileukemic effects of (213)Bi-lintuzumab, the first targeted α-emitter, after partially cytoreductive chemotherapy...
  21. ncbi request reprint Design and synthesis of 225Ac radioimmunopharmaceuticals
    Michael R McDevitt
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Appl Radiat Isot 57:841-7. 2002
    ..This process has yielded several potential novel targeted 225Ac-labeled immunotherapeutic agents that may now be evaluated in appropriate model systems and ultimately in humans...
  22. ncbi request reprint Engineered liposomes for potential alpha-particle therapy of metastatic cancer
    Stavroula Sofou
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Nucl Med 45:253-60. 2004
    ..Liposomes with encapsulated (225)Ac were developed to retain the potentially toxic daughters at the tumor site...
  23. pmc A self-assembling short oligonucleotide duplex suitable for pretargeting
    Prabodhika Mallikaratchy
    Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, New York, New York 10065, USA
    Nucleic Acid Ther 23:289-99. 2013
    ....
  24. pmc A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia
    Prabodhika R Mallikaratchy
    Sloan Kettering Institute, 1275 York Ave, New York, New York 10025, USA
    Nucleic Acids Res 39:2458-69. 2011
    ..The chemically engineered aptamers, with significantly improved kinetic and biochemical features, unique specificity and desirable pharmacological properties, may be useful in biomedical applications...
  25. pmc Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery
    J Justin Mulvey
    1 Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA 2 Weill Cornell Medical College, 468 East 68th Street, New York, New York 10065, USA 3
    Nat Nanotechnol 8:763-71. 2013
    ..Conjugates labelled with alpha-particle-generating (225)Ac were found to clear rapidly, thus mitigating radioisotope toxicity, and were shown to be therapeutically effective in vivo. ..
  26. ncbi request reprint Immunoreactivity assay for alpha-particle emitting monoclonal antibody constructs
    Anthony S Bonavia
    Molecular Pharmacology and Chemistry Department, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Appl Radiat Isot 64:470-4. 2006
    ..We have identified optimal cell fixation and immunoreactivity assay conditions and have validated them by performing the fixed-cell assay in clinical trials...
  27. ncbi request reprint Targeted nanomaterials for radiotherapy
    Freddy E Escorcia
    Memorial Sloan Kettering Cancer Center, Molecular Pharmacology and Chemistry Program, New York, NY 10021, USA
    Nanomedicine (Lond) 2:805-15. 2007
    ..Here, we will review some of the more common nanomaterials under investigation and their current and future applications as drug-delivery scaffolds with particular emphasis on targeted cancer radiotherapy...
  28. pmc Carbon nanotubes as vaccine scaffolds
    David A Scheinberg
    Molecular Pharmacology and Chemistry Program, Departments of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA Electronic address
    Adv Drug Deliv Rev 65:2016-22. 2013
    ..Early attempts demonstrating carbon nanotube-based vaccines can be used in both infectious disease settings and cancer are promising. ..
  29. ncbi request reprint Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers
    Rui Rong Yuan
    Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 104:2397-402. 2004
    ..Such an approach may allow a pathway to selective ablation of pathogenic T-cell clones ex vivo or in vivo without disturbing general immune function...
  30. pmc Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization
    Daniel J Nolan
    Cancer Genome Research Center, Cold Spring Harbor Laboratory, Woodbury, New York 11797, USA
    Genes Dev 21:1546-58. 2007
    ..Our results demonstrate that BM-derived EPCs are critical components of the earliest phases of tumor neoangiogenesis...

Research Grants2